Get the Stockscreener App
40.87
0.10%
0.075
Apellis Pharmaceuticals Inc stock is traded at $40.87, with a volume of 4.74M.
It is up +0.10% in the last 24 hours and up +115.57% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
See More
Previous Close:
$40.79
Open:
$40.73
24h Volume:
4.74M
Relative Volume:
0.96
Market Cap:
$5.22B
Revenue:
$1.00B
Net Income/Loss:
$22.39M
P/E Ratio:
330.89
EPS:
0.1235
Net Cash Flow:
$45.01M
1W Performance:
+0.49%
1M Performance:
+115.57%
6M Performance:
+69.13%
1Y Performance:
+110.24%
1-Day Range:
$40.70
$40.87
1-Week Range:
$40.60
$40.85
52-Week Range:
$16.10
$40.85
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
40.87 | 5.21B | 1.00B | 22.39M | 45.01M | 0.1235 |
VRTX
Vertex Pharmaceuticals Inc
|
440.40 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
742.49 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
809.48 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
332.95 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
305.10 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Jan-21-26 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-06-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
Valuation Update: Does Apellis Pharmaceuticals Inc stock have upside surprise potential - baoquankhu1.vn
Biogen lands two fast-growing drugs in blockbuster Apellis deal - MSN
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - Sahm
US Market Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsQuarterly Portfolio Report & High Return Trade Guides - baoquankhu1.vn
Apellis (APLS) director shifts 5,750 trust shares to spouse account - Stock Titan
Apellis Stock More Than Doubles on Biogen News. Here’s What to Know. - Barron's
Trading the Move, Not the Narrative: (APLS) Edition - Stock Traders Daily
Biogen’s Apellis Deal And High Dose SPINRAZA Shift Growth Outlook - Sahm
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? - Sahm
Apellis Pharmaceuticals Stock Rockets 140% With 6-Day Winning Streak - Trefis
6-Day Rally Sends Apellis Pharmaceuticals Stock Up 140% - Trefis
Apellis Pharmaceuticals stock reaches 52-week high at $40.71 By Investing.com - Investing.com Australia
Biogen (NASDAQ: APLS) readies tender offer for Apellis under March 31, 2026 deal - Stock Titan
Apellis Pharmaceuticals stock reaches 52-week high at $40.71 - Investing.com
Retail Surge: Can Apellis Pharmaceuticals Inc grow without dilution2026 Retail & Community Consensus Stock Picks - baoquankhu1.vn
RBC Adjusts Price Target on Apellis Pharmaceuticals to $41 From $21, Maintains Sector Perform Rating - marketscreener.com
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward - Benzinga
Apellis Pharmaceuticals Acquisition Under Investigation - National Today
Wellington files 13G/A owning 249,635 shares of Apellis (APLS) - Stock Titan
Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a ... - Bluefield Daily Telegraph
Shareholder Alert: Ademi LLP investigates whether Apellis - GlobeNewswire
5-Day Rally Sends Apellis Pharmaceuticals Stock Up 139% - Trefis
Apellis Pharmaceuticals Stock Surges 139%, With A 5-Day Winning Spree - Trefis
Biogen (NASDAQ: APLS) files Form 3 on Apellis voting group status - Stock Titan
Biogen Discloses Tender Offer at Apellis with 14.2% Stake - TradingView — Track All Markets
[SCHEDULE 13D] Apellis Pharmaceuticals, Inc. Major Shareholder Acquisition (>5%) - Stock Titan
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology - FinancialContent
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Biogen Paid a 140% Premium for Apellis. Was the $5.6B Deal Worth It? - TIKR.com
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get - Benzinga
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Apellis Pharmaceuticals, Inc. (APLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Apellis surges on $5.6B buyout deal with Biogen - MSN
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance
TD Cowen Maintains Apellis Pharmaceuticals (APLS) Buy Recommendation - MSN
APLS PE Ratio & Valuation, Is APLS Overvalued - Intellectia AI
Biogen Bets Big on Kidney Drugs with USD 5.6 Billion Apellis Pharmaceuticals Deal - Medical Dialogues
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy - Benzinga
Biogen to acquire Apellis in $5.6 billion deal - Ophthalmology Times
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded by Roth Mkm to "Hold" - marketbeat.com
Comparing Apellis Pharmaceuticals With Industry Competitors In Biotechnology Industry - Sahm
APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen - Stocktwits
Biogen’s $5.6 Billion Apellis Buy Drives Top Trading Volume Amid Share Price Slide - Bitget
Why Biogen Is Paying $5.6B to Buy Apellis Pharma - MedCity News
Apellis Pharmaceuticals (APLS): Mizuho Raises Price Target Amids - GuruFocus
Mizuho Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $41.00 - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded to "Hold" Rating by Jefferies Financial Group - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded to Hold Rating by Cantor Fitzgerald - MarketBeat
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):